BR100 Decreased By (-0.23%)
BR30 Decreased By (-0.61%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.81 Decreased By ▼ -0.22 (-3.65%)
BML 58.02 Increased By ▲ 5.27 (9.99%)
BOP 33.79 Decreased By ▼ -0.46 (-1.34%)
CNERGY 8.18 Increased By ▲ 0.02 (0.25%)
DCL 11.76 Decreased By ▼ -0.58 (-4.7%)
FCCL 53.34 Decreased By ▼ -0.55 (-1.02%)
FCSC 5.43 Increased By ▲ 0.21 (4.02%)
FFL 17.88 Decreased By ▼ -0.15 (-0.83%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.04 Decreased By ▼ -0.07 (-0.86%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.11 Decreased By ▼ -0.94 (-1.07%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.30 Increased By ▲ 0.36 (0.9%)
PIAHCLA 26.17 No Change ▼ 0.00 (0%)
PIBTL 17.10 Decreased By ▼ -0.22 (-1.27%)
PPL 228.48 Decreased By ▼ -4.30 (-1.85%)
PRL 34.55 Decreased By ▼ -0.40 (-1.14%)
PTC 67.43 Decreased By ▼ -0.13 (-0.19%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.88 Decreased By ▼ -0.29 (-1.07%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.33 Increased By ▲ 0.57 (6.51%)
TREET 24.56 Increased By ▲ 0.02 (0.08%)
TRG 71.50 Decreased By ▼ -0.25 (-0.35%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
World

White House considering intellectual property waiver for COVID-19 vaccines

  • Tai discussed the issue on Monday with drugmakers Pfizer and AstraZeneca PLC, noting her interest in a solution that gave developing countries a role in addressing critical gaps in vaccine production and distribution.
Published April 28, 2021 Updated April 28, 2021 01:55pm
By

WASHINGTON: The White House is considering options for maximizing global production and supply of COVID-19 vaccines at the lowest cost, including backing a proposed waiver of intellectual property rights, but no decision has been made, press secretary Jen Psaki said on Tuesday.

"There are a lot of different ways to do that. Right now, that's one of the ways, but we have to assess what makes the most sense," Psaki said, adding that US officials were studying whether it would be more effective to boost existing manufacturing of the vaccines in the United States.

US Trade Representative Katherine Tai had not made a recommendation on the issue, and President Joe Biden had not made a decision, she said.

US lawmakers and nonprofit groups are heaping pressure on the Biden administration to back the temporary patent waiver to help poor countries contain the pandemic as India and other countries battle a massive surge in cases.

The United States and several other countries have thus far blocked negotiations at the World Trade Organization (WTO) about a proposal led by India and South Africa that would waive the IP rights of pharmaceutical companies to allow developing countries to produce COVID-19 vaccines.

Proponents are pushing Washington to change course ahead of another WTO meeting on the issue on April 30.

Critics say waiving the WTO's agreement on Trade-Related Aspects of Intellectual Property could reduce the safety of vaccines, and that setting up production in new places would sap resources needed to boost production in existing locations.

Tai discussed the issue on Monday with drugmakers Pfizer and AstraZeneca PLC, noting her interest in a solution that gave developing countries a role in addressing critical gaps in vaccine production and distribution.

US industry executives believe Tai may be leaning toward backing the waiver after she called the gaping divide between developed and developing countries' access to medicines "completely unacceptable" and said industry needed to make sacrifices in times of crisis.

Comments

Comments are closed for this article.